{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:09:46Z","timestamp":1789074586681,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pcd.2026.07.015","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:18:22Z","timestamp":1785874702000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regional and national trends in prescription of guideline directed cardio-kidney protective medications in people with type 2 diabetes and cardio-kidney disease"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-9603","authenticated-orcid":false,"given":"Shubham","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujeeb A.","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsea","family":"Marble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8883-8562","authenticated-orcid":false,"given":"Christine","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-1584","authenticated-orcid":false,"given":"Michael E.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"ElNakieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pcd.2026.07.015_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"issue":"9854","key":"10.1016\/j.pcd.2026.07.015_bib2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2026.07.015_bib3","doi-asserted-by":"crossref","unstructured":"Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears in N Engl J Med. 2009 Sep 3;361(10):1028] [published correction appears in N Engl J Med. 2009 Sep 3;361(10):1024-5]. N Engl J Med. 2009;360(2):129-139. https:\/\/doi.org\/10.1056\/NEJMoa0808431.","DOI":"10.1056\/NEJMc096250"},{"issue":"24","key":"10.1016\/j.pcd.2026.07.015_bib4","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2026.07.015_bib5","doi-asserted-by":"crossref","unstructured":"Ismail-Beigi F., Craven T., Banerji M.A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial [published correction appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet. 2010;376(9739):419-430. https:\/\/doi.org\/10.1016\/S0140-6736(10)60576-4.","DOI":"10.1016\/S0140-6736(10)60576-4"},{"issue":"22","key":"10.1016\/j.pcd.2026.07.015_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.pcd.2026.07.015_bib7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.pcd.2026.07.015_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.pcd.2026.07.015_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.pcd.2026.07.015_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2026.07.015_bib11","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo controlled trial","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10157","key":"10.1016\/j.pcd.2026.07.015_bib12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.pcd.2026.07.015_bib13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.pcd.2026.07.015_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.pcd.2026.07.015_bib15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pcd.2026.07.015_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.pcd.2026.07.015_bib17","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use, and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR(R) Research to Practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"2","key":"10.1016\/j.pcd.2026.07.015_bib18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.14245","article-title":"Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012\u20132019","volume":"23","author":"Funck","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2026.07.015_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2023.05.002","article-title":"Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry","volume":"263","author":"Arnold","year":"2023","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.pcd.2026.07.015_bib20","first-page":"S90","article-title":"American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pcd.2026.07.015_bib21","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pcd.2026.07.015_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/1753-0407.13363","article-title":"Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics","volume":"15","author":"Lingvay","year":"2023","journal-title":"J. Diabetes"},{"issue":"9","key":"10.1016\/j.pcd.2026.07.015_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023811","article-title":"National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015\u20132020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.pcd.2026.07.015_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41574-023-00923-3","article-title":"SGLT inhibitors: a serendipitous glycaemic tale","volume":"20","author":"Agarwal","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"10.1016\/j.pcd.2026.07.015_bib25","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.pcd.2026.07.015_bib26","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J. R. Soc. Med."},{"issue":"3","key":"10.1016\/j.pcd.2026.07.015_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/ehjcvp\/pvz058","article-title":"Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice","volume":"6","author":"Slater","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"8","key":"10.1016\/j.pcd.2026.07.015_bib28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11886-022-01715-3","article-title":"Synchronous Health Care Delivery for the Optimization of Cardiovascular and Renal Care in Patients with Type 2 Diabetes","volume":"24","author":"Alqahtani","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"issue":"1","key":"10.1016\/j.pcd.2026.07.015_bib29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12913-025-12270-2","article-title":"Nationwide guideline implementation: a qualitative study of barriers and facilitators from the perspective of guideline organizations","volume":"25","author":"Thoonsen","year":"2025","journal-title":"BMC Health Serv. Res."},{"issue":"8","key":"10.1016\/j.pcd.2026.07.015_bib30","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2016.11.004","volume":"69","author":"Chan","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.pcd.2026.07.015_bib31","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR\u00ae Research to Practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.pcd.2026.07.015_bib32","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/dc23-Srev","article-title":"Summary of Revisions: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991826001488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991826001488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:42:55Z","timestamp":1789072975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991826001488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1751991826001488"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2026.07.015","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regional and national trends in prescription of guideline directed cardio-kidney protective medications in people with type 2 diabetes and cardio-kidney disease","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2026.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.","name":"copyright","label":"Copyright"}]}}